Evidence map›Paper›PMID 40140908›Full record

ArticleActa neuropathologica communications2025

C9ORF72 poly-PR disrupts expression of ALS/FTD-implicated STMN2 through SRSF7.

Karen S Wang, Julie Smeyers, Kevin Eggan, Bogdan Budnik, Daniel A Mordes

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Karen S Wang *Institute for Neurodegenerative Diseases, University of California, San Francisco, CA, USA.
Julie Smeyers *Institute for Neurodegenerative Diseases, University of California, San Francisco, CA, USA.
Kevin EgganDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Bogdan BudnikMass Spectrometry and Proteomic Laboratory, FAS Division of Science, Harvard University, Cambridge, MA, USA.
Daniel A MordesInstitute for Neurodegenerative Diseases, University of California, San Francisco, CA, USA. daniel.mordes@ucsf.edu.

Funding

C9ORF72 in Motor System Biology and ALSR01NS089742 · NINDS · HARVARD UNIVERSITY · PI EGGAN, KEVIN C · 2014 to 2018
$2.3M
Novel pathways in C9ORF72-associated ALS and dementiaK08NS104270 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MORDES, DANIEL ADAM · 2019 to 2023
$995k
NINDS NIH HHS K08 NS104270NINDS NIH HHS K08NS104270NINDS NIH HHS R01 NS089742
6 · The paper itself

Abstract

A hexanucleotide repeat expansion in C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and combined ALS/FTD. The repeat is transcribed in the sense and the antisense directions to produce several dipeptide repeat proteins (DPRs) that have toxic gain-of-function effects; however, the mechanisms by which DPRs lead to neural dysfunction remain unresolved. Here, we observed that poly-proline-arginine (poly-PR) was sufficient to inhibit axonal regeneration of human induced pluripotent stem cell (iPSC)-derived neurons. Global phospho-proteomics revealed that poly-PR selectively perturbs nuclear RNA binding proteins (RBPs). In neurons, we found that depletion of one of these RBPs, SRSF7 (serine/arginine-rich splicing factor 7), resulted in decreased abundance of STMN2 (stathmin-2), though not TDP-43. STMN2 supports axon maintenance and repair and has been recently implicated in the pathogenesis of ALS/FTD. We observed that depletion of SRSF7 impaired axonal regeneration, a phenotype that could be rescued by exogenous STMN2. We propose that antisense repeat-encoded poly-PR perturbs RBPs, particularly SRSF7, resulting in reduced STMN2 and axonal repair defects in neurons. Hence, we provide a potential link between DPRs gain-of-function effects and STMN2 loss-of-function phenotypes in neurodegeneration.

Indexed as

Amyotrophic Lateral SclerosisC9orf72 ProteinFrontotemporal DementiaSerine-Arginine Splicing FactorsAxonsDNA Repeat ExpansionHumansInduced Pluripotent Stem CellsNeuronsC9orf72 ProteinC9orf72 protein, humanSerine-Arginine Splicing Factors

Identifiers

PMID40140908
PMCPMC11948778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.